- Home
- MGNX vs NCTY Comparison
MGNX vs NCTY Comparison
Compare MGNX & NCTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- NCTY
- Stock Information
- Founded
- MGNX 2000
- NCTY 1999
- Country
- MGNX United States
- NCTY China
- Employees
- MGNX N/A
- NCTY N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- NCTY Business Services
- Sector
- MGNX Health Care
- NCTY Consumer Discretionary
- Exchange
- MGNX Nasdaq
- NCTY Nasdaq
- Market Cap
- MGNX 151.9M
- NCTY 148.0M
- IPO Year
- MGNX 2013
- NCTY 2004
- Fundamental
- Price
- MGNX $2.20
- NCTY $11.47
- Analyst Decision
- MGNX Hold
- NCTY
- Analyst Count
- MGNX 10
- NCTY 0
- Target Price
- MGNX $7.17
- NCTY N/A
- AVG Volume (30 Days)
- MGNX 551.0K
- NCTY 69.1K
- Earning Date
- MGNX 05-08-2025
- NCTY 01-01-0001
- Dividend Yield
- MGNX N/A
- NCTY N/A
- EPS Growth
- MGNX N/A
- NCTY N/A
- EPS
- MGNX N/A
- NCTY 9.91
- Revenue
- MGNX $141,329,000.00
- NCTY $24,286,983.00
- Revenue This Year
- MGNX $177.84
- NCTY N/A
- Revenue Next Year
- MGNX N/A
- NCTY N/A
- P/E Ratio
- MGNX N/A
- NCTY $2.62
- Revenue Growth
- MGNX 16.68
- NCTY 2.82
- 52 Week Low
- MGNX $2.15
- NCTY $4.90
- 52 Week High
- MGNX $19.54
- NCTY $20.59
- Technical
- Relative Strength Index (RSI)
- MGNX 35.93
- NCTY 40.08
- Support Level
- MGNX $2.16
- NCTY $10.60
- Resistance Level
- MGNX $2.49
- NCTY $12.07
- Average True Range (ATR)
- MGNX 0.17
- NCTY 1.28
- MACD
- MGNX -0.00
- NCTY -0.03
- Stochastic Oscillator
- MGNX 7.87
- NCTY 16.11
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China and other areas.